Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 39009452 | 2024 | Novel insights into paclitaxel's role on tumor-associated macrophages in enhancing PD-1 blockade in breast cancer treatment. Journal for immunotherapy of cancer Likely relevant The study tests paclitaxel and PD-1 blockade in patient data, in vitro macrophages, and in vivo murine models, measuring macrophage cross-presentation and CD8+ T cell responses. | paclitaxel; PD-1 blockade | Mixed | triple-negative breast cancer | paclitaxel 21/5/8; PD-1 blockade 0/0/0 | Awaiting curator check |
| 39076248 | 2024 | Targeted opening of the blood-brain barrier facilitates doxorubicin/anti-PD-1-based chemoimmunotherapy of glioblastoma. Oncoimmunology Likely relevant The article experimentally tests doxorubicin and anti-PD-1 in a tumor-bearing animal model and reports effects on immunogenic cell death and immunotherapy sensitization. | doxorubicin; anti-PD-1 | Animal | glioblastoma | doxorubicin 22/9/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 39078050 | 2024 | MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody. Gut microbes Likely relevant The study tests the postbiotic MS-20 combined with anti-PD1 antibody in xenograft mouse models and measures immunological changes in the tumor microenvironment like CD8+ T cell infiltration. | MS-20 (Symbiota); anti-programmed cell death 1 (PD1) antibody | Animal | colon and lung cancer | MS-20 (Symbiota) 0/0/0; anti-programmed cell death 1 (PD1) antibody 0/0/0 | Awaiting curator check |
| 39078728 | 2024 | Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF. Clinical cancer research : an official journal of the American Association for Cancer Research Likely relevant Evaluates the impact of LIF blockade and combination with immune checkpoint inhibitors using primary cell cultures, animal models, and patient-derived models, measuring cytokine levels and CD8 T cell infiltration. | blocking antibodies against LIF; immune checkpoint inhibitors | Mixed | cervical cancer | blocking antibodies against LIF 0/0/0; immune checkpoint inhibitors 0/0/0 | Awaiting curator check |
| 39095793 | 2024 | Genome-wide CRISPR screening identifies tyrosylprotein sulfotransferase-2 as a target for augmenting anti-PD1 efficacy. Molecular cancer Likely relevant The study tests TPST2 genetic loss-of-function and its combinatorial effect with anti-PD1 therapy in mouse syngeneic models, measuring IFNγ signaling, HLA expression, and tumor-infiltrating lymphocytes. | anti-PD1 | Animal | cancer | anti-PD1 1/1/0 | Awaiting curator check |
| 39107132 | 2024 | Targeting tumor-associated macrophage-derived CD74 improves efficacy of neoadjuvant chemotherapy in combination with PD-1 blockade for cervical cancer. Journal for immunotherapy of cancer Likely relevant The study examines neoadjuvant chemotherapy combined with PD-1 blockade in human samples and in vitro/in vivo models, measuring macrophage phagocytosis and cell-cell interactions. | neoadjuvant chemotherapy; PD-1 blockade | Mixed | cervical cancer | neoadjuvant chemotherapy 0/0/0; PD-1 blockade 0/0/0 | Awaiting curator check |
| 39137404 | 2024 | YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer. Cancer research Likely relevant The study tests anti-PD-1 treatment in vivo alongside genetic targeting, measuring CD8+ T-cell infiltration and activation. | anti-PD-1 | Animal | prostate cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 39137819 | 2024 | Functional co-delivery nanoliposomes based on improving hypoxia for increasing photoimmunotherapy efficacy of cold tumors. International journal of pharmaceutics Likely relevant Tests a functional co-delivery nanoliposome (photodynamic therapy and metformin) in animal models and measures immunogenic cell death, T cell activation, and PD-L1 reduction. | MET-HMME/CAT-HMME@Nlip; metformin | Animal | hypoxic cold tumors | MET-HMME/CAT-HMME@Nlip 0/0/0; metformin 0/0/0 | Awaiting curator check |
| 39168966 | 2024 | A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma. Nature communications Likely relevant Evaluates atezolizumab and bevacizumab in a clinical trial and measures CD8+ T cell infiltration and CD68+ monocytes in patient samples. | atezolizumab; bevacizumab | Patient | malignant mesothelioma | atezolizumab 0/0/4; bevacizumab 0/0/7 | Awaiting curator check |
| 39181134 | 2024 | Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization. Cell reports. Medicine Likely relevant The study screens and tests FDA-approved small-molecule drugs (including COX1/2 inhibitors) in combination with alpha-PD-L1 in tumor models, measuring T cell expansion and CD8+ T cell responses. | alpha-PD-L1; cyclooxygenase (COX)1/2 inhibitors | Animal | triple-negative breast cancer | alpha-PD-L1 0/0/0; cyclooxygenase (COX)1/2 inhibitors 0/0/0 | Awaiting curator check |
| 39187583 | 2024 | Metal-ion-chelating phenylalanine nanostructures reverse immune dysfunction and sensitize breast tumour to immune checkpoint blockade. Nature nanotechnology Likely relevant The study tests metal-ion-chelating L-phenylalanine nanostructures combined with starvation in tumour-bearing animals and measures their effects on dendritic cell activation and cytotoxic T lymphocyte responses. | metal-ion-chelating L-phenylalanine nanostructures; immune checkpoint blockade | Animal | breast and colorectal tumours | metal-ion-chelating L-phenylalanine nanostructures 0/0/0; immune checkpoint blockade 0/1/0 | Awaiting curator check |
| 39214650 | 2024 | Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment. Journal for immunotherapy of cancer Likely relevant The study analyzes paired tumor biopsies and blood samples from clinical trials evaluating eganelisib combined with atezolizumab and chemotherapy, reporting macrophage reprogramming and systemic immune activation. | eganelisib; atezolizumab; nab-paclitaxel | Patient | triple-negative breast cancer | eganelisib 0/0/0; atezolizumab 0/0/4; nab-paclitaxel 0/0/0 | Awaiting curator check |
| 39223929 | 2024 | Targeting SRSF10 might inhibit M2 macrophage polarization and potentiate anti-PD-1 therapy in hepatocellular carcinoma. Cancer communications (London, England) Likely relevant The study tests a pharmacological inhibitor of SRSF10 (1C8) and PD-1 monoclonal antibodies in vitro, in vivo, and in organotypic spheroids, measuring M2 macrophage polarization and CD8+ T cell responses. | 1C8; programmed cell death 1 (PD-1) monoclonal antibodies | Mixed | hepatocellular carcinoma | 1C8 0/0/0; programmed cell death 1 (PD-1) monoclonal antibodies 0/0/0 | Awaiting curator check |
| 39225102 | 2024 | Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models. The Journal of clinical investigation Likely relevant Experimentally tests pharmacological LDH inhibition alone and with immune checkpoint blockade in murine cancer models, measuring T cell metabolic changes, infiltration, and function. | LDH inhibitors; immune checkpoint blockade | Animal | melanoma and colon cancer | LDH inhibitors 0/0/0; immune checkpoint blockade 0/1/0 | Awaiting curator check |
| 39227567 | 2024 | Mitochondrial rewiring with small-molecule drug-free nanoassemblies unleashes anticancer immunity. Nature communications Likely relevant The study experimentally tests small-molecule nanoassemblies and PD-1 blockade in preclinical mouse models, measuring immune-related outcomes like immunogenic cell death, tumor immunogenicity, and antitumor immunity. | small-molecule drug-free nanoassemblies; PD-1 blockade | Animal | cancer | small-molecule drug-free nanoassemblies 0/0/0; PD-1 blockade 0/0/0 | Awaiting curator check |
| 39244215 | 2024 | Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade. Journal for immunotherapy of cancer Likely relevant Investigates the role of angiotensin receptor blockers in tumor models and their impact on transforming the tumor microenvironment to enhance ICB. | angiotensin receptor blocker; ARB | Mixed | unspecified | angiotensin receptor blocker 0/0/0; ARB 8/1/3 | Awaiting curator check |
| 39288081 | 2024 | Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cancer. Cancer research Likely relevant The study tests chloroquine, Flt3 ligand, and anti-LAG3 antibody in mouse models and measures DC activation and T cell infiltration. | chloroquine; Flt3 ligand; anti-LAG3 antibody | Animal | pancreatic cancer | chloroquine 3/0/1; Flt3 ligand 0/0/0; anti-LAG3 antibody 0/0/0 | Awaiting curator check |
| 39298276 | 2024 | Targeting heterogeneous tumor microenvironments in pancreatic cancer mouse models of metastasis by TGF-β depletion. JCI insight Likely relevant The study tests a TGF-beta trap (AVID200/BMS-986416) combined with anti-PD-1 in PDAC murine models and analyzes immune microenvironment modulation. | AVID200/BMS-986416; anti-PD-1 | Animal | pancreatic ductal adenocarcinoma | AVID200/BMS-986416 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 39325056 | 2024 | Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti-PD-1 in Murine Non-Small Cell Lung Cancer. Cancer immunology research Likely relevant Tests an engineered viral vaccine combined with anti-PD-1 in murine models and measures T cell responses and type I IFN. | hyper-IFN-sensitive influenza viral vaccine; anti-PD-1 | Animal | non-small cell lung cancer | hyper-IFN-sensitive influenza viral vaccine 0/0/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 39331709 | 2024 | ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer. Science advances Likely relevant The study tests ATR inhibition combined with PD-L1 blockade or topotecan in cell/mouse models and patient samples, measuring immune readouts such as STING signaling, T cell recruitment, and MHC class I expression. | berzosertib; topotecan; programmed death-ligand 1 (PD-L1) inhibitor | Mixed | small-cell lung cancer | berzosertib 0/0/0; topotecan 14/1/0; programmed death-ligand 1 (PD-L1) inhibitor 0/0/0 | Awaiting curator check |
| 39358663 | 2024 | PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis. Cancer immunology, immunotherapy : CII Likely relevant The study evaluates the administration of anti-PD-1 antibodies and EpCAM-directed CAR T-cells in an in vivo murine model, measuring intratumoral CAR T-cell densities and persistence. | anti-PD-1; EpCAM-directed CAR T-cell | Animal | lung cancer brain metastasis | anti-PD-1 14/36/0; EpCAM-directed CAR T-cell 0/0/0 | Awaiting curator check |
| 39385035 | 2024 | CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature Likely relevant Evaluates immune checkpoint inhibitors and chemotherapy in mouse models and patients, assessing T cell subsets and myeloid cell phenotypes. | durvalumab; tremelimumab; chemotherapy | Mixed | non-small-cell lung cancer | durvalumab 0/0/2; tremelimumab 0/0/0; chemotherapy 2/0/3 | Awaiting curator check |
| 39419025 | 2024 | IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell Likely relevant Investigates how the ER stress sensor IRE1alpha restricts taxane-induced immunostimulatory effects and pyroptosis in triple-negative breast cancer cells. | taxane | Cell line | Triple-Negative Breast Cancer | taxane 1/0/1 | Awaiting curator check |
| 39420389 | 2024 | Novel combination therapy using recombinant oncolytic adenovirus silk hydrogel and PD-L1 inhibitor for bladder cancer treatment. Journal of nanobiotechnology Likely relevant The study evaluates the combination of a recombinant oncolytic adenovirus silk hydrogel and a PD-L1 inhibitor in a murine bladder cancer model, measuring T-cell infiltration and immune responses. | recombinant oncolytic Adv-loaded silk hydrogel; PD-L1 inhibitor | Animal | bladder cancer | recombinant oncolytic Adv-loaded silk hydrogel 0/0/0; PD-L1 inhibitor 0/0/0 | Awaiting curator check |
| 39423284 | 2024 | Programmable bacteria synergize with PD-1 blockade to overcome cancer cell-intrinsic immune resistance mechanisms. Science immunology Likely relevant The study experimentally tests engineered bacteria releasing IFN-gamma combined with PD-1 blockade in tumor-bearing animals and measures their effects on CD4+, CD8+ T cells, and NK cells. | IFN-gamma; PD-1 blockade | Animal | cancer | IFN-gamma 0/0/0; PD-1 blockade 0/0/0 | Awaiting curator check |